Buoyed by new results from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's ...

When an Alzheimer’s drug recently gained a second chance from European regulators after an initial rejection, the decision ...

A further presentation during the same symposium at AD/PD 2025 focused on how MRI methods could be accelerated to improve ...

Weight loss drugs such as semaglutide, found in Ozempic and Wegovy, are tied to a 40% reduced risk of an Alzheimer's disease ...

The EMA's human medicines committee has said it does not recommend approval of Eli Lilly's anti-amyloid Alzheimer's disease treatment Kisunla, saying its modest benefits don't outweigh its risks.

Biopharma leaders react to the forced resignation of CBER Head Peter Marks as RFK Jr.’s promised job cuts begin at the FDA; ...

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...

Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...

A proposed ballot measure in California named after Luigi Mangione, the suspected killer of UnitedHealthcare CEO Brian ...

Sleep deficiency was associated with atrophy of the inferior parietal region, which is observed in early Alzheimer's disease. (Journal of Clinical Sleep Medicine) Researchers assessed evidence ...

A European regulatory committee rejected Eli Lilly's U.S.-approved Alzheimer's disease treatment over potentially dangerous risks of brain bleeding and swelling.